|Articles|August 1, 2012
- Pharmaceutical Executive-08-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - August 2012
Piramal Pivots for Growth
Advertisement
Articles in this issue
almost 14 years ago
Country Report: Mexicoalmost 14 years ago
Sunny Outlook for Biopharm 2020?almost 14 years ago
The Phrase that Playsalmost 14 years ago
Planning that Thousand Year FutureAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
2
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
3
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
4
FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections
5